KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EBITDA (2017 - 2025)

Historic EBITDA for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to -$260.0 million.

  • Moderna's EBITDA fell 27142.86% to -$260.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 billion, marking a year-over-year decrease of 2859.26%. This contributed to the annual value of -$3.9 billion for FY2024, which is 693.56% up from last year.
  • As of Q3 2025, Moderna's EBITDA stood at -$260.0 million, which was down 27142.86% from -$907.0 million recorded in Q2 2025.
  • Over the past 5 years, Moderna's EBITDA peaked at $5.4 billion during Q4 2021, and registered a low of -$2.0 billion during Q3 2023.
  • Its 5-year average for EBITDA is $648.2 million, with a median of -$70.0 million in 2024.
  • Per our database at Business Quant, Moderna's EBITDA surged by 260983.61% in 2021 and then crashed by 2086666.67% in 2024.
  • Moderna's EBITDA (Quarter) stood at $5.4 billion in 2021, then plummeted by 70.79% to $1.6 billion in 2022, then crashed by 99.62% to $6.0 million in 2023, then crashed by 20866.67% to -$1.2 billion in 2024, then surged by 79.13% to -$260.0 million in 2025.
  • Its last three reported values are -$260.0 million in Q3 2025, -$907.0 million for Q2 2025, and -$1.0 billion during Q1 2025.